Tacrolimus ointment highly efficacious for treatment of facial vitiligo: Study
France: Twice-daily tacrolimus 0.1% ointment over a 6-month course was found to be highly effective for the treatment of facial vitiligo, according to a recent study in the Journal of Investigative Dermatology.
Relapses occurred in 40% of the included patients highlighting the need for maintenance therapy following treatment success.
Topical calcineurin inhibitors are widely used off label in vitiligo. However, there is a lack of placebo-controlled, blinded studies that support their use. Considering this, Khaled Ezzedine, UPEC-Université Paris-Est Créteil, France, and colleagues aimed to compare the efficacy of tacrolimus 0.1% ointment versus vehicle for repigmentation in adult patients with facial vitiligo.
For the purpose, the researchers performed a 24-week multicenter randomized parallel double-blind study with a 24-week post-treatment follow-up extension. It included 42 adult patients with recent facial vitiligo target lesions (<2years) without changes in pigmentation or size over the prior 3 months.
The patients were randomized to receive either tacrolimus 0.1% ointment or vehicle twice daily.
The primary outcome was therapeutic success, defined as a change in repigmentation of the target lesion ≥ 75% between baseline and week 24, measured by ImageJ software.
Key findings of the study include:
- Therapeutic success was achieved in 65% of tacrolimus-treated patients versus 0% in vehicle-treated patients at week 24.
- Only 40% of relapse was observed at 48 weeks.
- Side effects were negligible, consistent with more than 20 years of data regarding overall tacrolimus treatment.
"Twice-daily tacrolimus 0.1% ointment showed superior efficacy, compared with vehicle, through 24 weeks of intervention and 24 weeks of follow-up in adult patients with facial vitiligo," wrote the authors. "Maintenance intermittent treatment was justified because relapses occurred over 6 months in 40% of the included patients."
The study titled, "Efficacy and safety of tacrolimus 0.1% for the treatment of facial vitiligo: a multicenter randomized, double-blinded, vehicle-controlled study," is published in the Journal of Investigative Dermatology.
DOI: https://www.jidonline.org/article/S0022-202X(21)00077-4/fulltext
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.